HC Wainwright & Co. Maintains Buy on MiNK Therapeutics, Lowers Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Emily Bodnar maintains a Buy rating on MiNK Therapeutics (NASDAQ:INKT) but lowers the price target from $10 to $9.
March 21, 2024 | 3:27 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
MiNK Therapeutics maintains a Buy rating by HC Wainwright & Co., though its price target was reduced from $10 to $9.
While the reduction in price target could suggest a tempered outlook on the stock's potential, the maintenance of a Buy rating indicates a continued positive view on the company's fundamentals. This mixed signal could lead to neutral short-term price movement as investors weigh the implications.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100